

ForPatients

by Roche

Small Cell Lung Cancer Small Cell Lung Carcinoma

Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/ Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT04622228 ML42391

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a Phase II, single arm, multicenter study designed to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) concurrent cisplatin/carboplatin plus etoposide with atezolizumab in participants who have extensive-stage small cell lung cancer (ES-SCLC) and are chemotherapy-naïve for their extensive-stage disease.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT04622228 ML42391
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
